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Abstract  Fosfomycin  is  a  broad  spectrum  antibiotic,  belonging  to  the  group  of  phosphonic  acid
antibiotics  that  is  active  against  most  urinary  tract  pathogens.  It  is  an  effective  and  safe  antibi-
otic for  the  treatment  of  uncomplicated  urinary  tract  infections,  which  makes  it  a  frequently
used drug  in  our  country  in  this  clinical  setting.  In  general,  it  is  well-tolerated  and  does  not
appear to  cause  serious  reactions.  Most  reactions  are  gastrointestinal.  Hepatotoxicity  with  this
drug has  been  rarely  described.We  report  a  case  of  acute  hepatitis  induced  by  a  single  3  g  dose
of fosfomycin,  in  a  previously  healthy  female  adult.
© 2010  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Hepatite  aguda  induzida  por  fosfomicina:  relato  de  um  caso  clínico  e  revisão
da  literatura
Resumo  A  fosfomicina  é  um  antibiótico  de  largo  espectro,  que  pertence  ao  grupo  do  ácido
fosfónico  e  é  eﬁcaz  contra  a  maioria  dos  microorganismos  do  tracto  urinário.  Pela  sua  eﬁcácia  e
seguranc¸a no  tratamento  de  infecc¸ões  do  tracto  urinário  não  complicadas  é  amplamente  usado
no nosso  país  nesta  situac¸ão  clínica.  É  um  fármaco  geralmente  bem  tolerado  e  que  não  parece
causar efeitos  adversos  graves.  A  maioria  dos  efeitos  laterais  relatada  é  gastrointestinal.  A  hep-
atotoxicidade  induzida  com  a  fosfomicina  tem  sido  raramente  descrita.Os  autores  descrevem
um caso  de  hepatite  aguda  induzida  por  uma  dose  única  de  3  g  de  fosfomicina,  numa  doente
adulta previamente  saudável.
©  2010  Sociedade  Portuguesa  de
direitos reservados.
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Figure  1  Expanded  portal  space  with  discrete  ﬁbrosis  and
intense inﬂammatory  inﬁlltrate  (composed  by  lymphocytes,
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bin  continued  to  rise  and  reached  a  peak  40  days  after  the
intake  of  fosfomycin,  and  then  it  also  started  to  decline
(Fig.  3).  The  patient  improved  symptomatically,  in  parallel64  
ntroduction
osfomycin  is  an  oral  antibiotic  derived  from  phosphonic
cid  that  has  been  widely  used  in  the  treatment  of  uncom-
licated  urinary  tract  infections.1,2 Its  potent  and  enduring
ctivity  against  urinary  pathogens  has  been  conﬁrmed  in
urope3 and  USA.4 Since  1988  fosfomycin  has  been  exten-
ively  used  in  several  European  countries  for  single-dose
herapy  of  uncomplicated  urinary  tract  infections.  After  a
ingle  3  g  dose,  fosfomycin  exhibits  very  high  and  sustained
rinary  concentrations  that  rapidly  kill  pathogens  reducing
he  opportunity  for  mutant  selection.  The  resistance  rates
f  fosfomycin  remain,  therefore,  extremely  low  (about  1%)
orldwide.5 Furthermore,  fosfomycin  is  well  tolerated,  with
 low  incidence  of  adverse  events.  These  consist  mainly  of
astrointestinal  symptoms  that  are  ordinarily  transient,  mild
nd  self-limiting.1,6
The  authors  present  a  case  of  a  24-year-old  woman  with
cute  hepatitis  induced  by  a  single  3  g  dose  of  fosfomycin
or  acute  cystitis.
ase report
 24-year-old  woman,  with  no  signiﬁcant  past  medical  his-
ory,  presented  to  the  emergency  department  with  nausea,
atigue,  increasing  muscle  weakness,  gradually  worsening
aundice  and  dark  urine,  for  four  weeks.  The  symptoms
tarted  one  week  after  taking  a  single  3  g  dose  of  fosfomycin
or  acute  cystitis.  She  denied  any  accompanying  symptoms,
uch  as  rash,  arthralgias,  fever  or  adenopathies.
She  also  denied  taken  any  other  medications  includ-
ng  over-the  counter  medications,  herbal  or  traditional
edicines.  There  was  no  history  of  drugs  or  alcohol  abuse,
ast  administration  of  blood  products  or  blood  transfusion,
r  previous  hepatitis.  She  denied  recent  travels.  There  was
o  family  history  of  liver  diseases.
On  physical  examination,  the  vital  signs  were  normal  and
here  were  no  remarkable  ﬁndings  except  for  icteric  skin
nd  sclera.  Abdominal  and  neurological  examinations  were
ormal.
The  hematological  data  revealed  hemoglobin  of
2.6  g/dL;  total  white  cell  count  of  11,  8  × 103/L  (3.3%
f  lymphocytes  and  0.5%  of  eosinophils);  platelet  count  of
37  ×  103/L  and  prothrombin  time  of  14  s  (INR  1.2).  The
esults  of  liver  tests  were:  total  bilirubin  195  mol/L
NR:  <22)  with  124  mol/L  of  conjugated,  alanine
minotransferase  (ALT)  1833  IU/L  (NR:  10--66),  aspar-
ate  aminotransferase  1467  IU/L  (NR:  15--46),  alkaline
hosphatase  (ALP)  86  IU/L  (NR  38--136),  gamma-glutamyl
ransferase  68  IU/L  (NR:  12--58)  and  LDH  1531  IU/L  (NR:
13--618).
Electrolytes,  serum  albumin,  iron  and  transferrin  satu-
ation  were  normal.  IgM  anti-HAV,  HBsAg,  IgM  anti-HBc  and
nti-HCV  antibodies  were  negative.  Anti-HIV,  anti-CMV,  anti-
BV  and  anti-HSV  were  also  negative.  Auto-antibodies  (ANA,
NCA,  Anti-LKM,  AMA  and  ASMA)  were  negative.  24  h-urinary
opper,  ceruloplasmin,  -fetoprotein  and  -1  antitrypsin
ere  within  normal  range.  Liver  ultrasonography  showed  no
igniﬁcant  abnormality  except  for  increased  echogenicity.
A  liver  biopsy  by  percutaneous  route  was  then  performed
ithout  complications.  The  biopsy  material  was  fragmented
F
h
aosinophils  and  few  neutrophils).  There  are  discrete  lesions  of
nterface  hepatitis  (hematoxilin  and  eosin,  400×).
nd  had  lesions  located  in  the  portal  spaces  and  hepatic
obules.  The  histological  examination  showed  expansion  of
he  portal  spaces  with  scant  ﬁbrosis  and  intense  inﬂamma-
ory  inﬁltrate  composed  by  lymphocytes,  eosinophils  and
ew  neutrophils.  There  were  also  focal  lesions  of  interface
epatitis  (Fig.  1).  The  hepatic  lobules  showed  moderate
nﬂammatory  inﬁltrate,  similar  to  the  one  noticed  in
he  portal  spaces,  ballooning  degeneration  of  the  hepa-
ocytes  (Fig.  2)  and  isolated  apoptotic  bodies  throughout
he  entire  studied  material.  It  was  observed  focal  hepatic
ecrosis  with  collapse  of  the  parenchyma,  more  severe  in
he  perivenular  zone,  along  with  discrete  ﬁbrosis.  There  was
lso  focal  hepatic  steatosis.  No  granulomas  were  detected.
hese  ﬁndings  were  consistent  with  acute  hepatitis  and  were
ighly  compatible  with  toxic/pharmacological  etiology.
A  gradual  decrease  in  liver  enzymes  was  seen;  total  biliru-igure  2  Hepatic  lobule  with  balloning  degeneration  of  the
epatocytes  and  sparse  inﬂammatory  inﬁltrate  (hematoxilin
nd eosin,  400×).
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aFigure  3  Evolution  of  aminotransfer
with  the  decline  in  aminotransaminases.  Three  months  after
fosfomycin  intake,  all  liver  function  tests  had  normalized
(Fig.  3).
Two  years  after,  the  patient  remains  asymptomatic  and
without  alteration  of  the  liver  enzymes.
Discussion
Fosfomycin  is  a  widely  used,  broad-spectrum  antibiotic,
which  exhibits  a  rapid  bactericidal  activity  against  a
large  number  of  aerobic  Gram  positive  and  Gram-negative
bacteria.1,2 It  is  approved  as  a  single-dose  therapy  (3-g
oral  dose)  for  the  treatment  of  uncomplicated  urinary  tract
infections  (acute  cystitis)  in  women.7
Usually,  it  is  a  well-tolerated  drug  and  does  not  appear
to  cause  serious  reactions.
Reported  adverse  events  are  usually  mild  and  last  only
1--2  days,  resolving  without  treatment.  The  overall  inci-
dence  of  side-effects  is  6%  with  oral  therapeutic  dosing  and
17%  with  parenteral  administration.  Gastrointestinal  com-
plaints,  mostly  diarrhea,  are  the  most  frequent.  Dizziness,
headache  and  vaginitis  have  also  been  reported.6 In  terms
of  liver  adverse  events,  only  rare  cases  of  asymptomatic  and
mild  liver  enzyme  abnormalities  have  been  described.8
To  our  knowledge  there  are  three  cases  in  the  litera-
ture  of  fosfomycin  induced-liver  injury:  a  case  of  recurrent
fosfomycin-induced  hepatic  toxicity  with  drug  rechallenge
in  a  30-year-old  woman  with  cystic  ﬁbrosis  in  France,9 a  case
of  acute  severe  hepatitis  in  Japan10 and  a  case  of  fosfomycin-
induced  liver  disease  in  a  50-year-old  woman  in  China.11
The  authors  have  no  additional  information  about  the  case
reported  in  Japan  because  this  article  was  published  in
Japanese.  In  the  other  two  cases,  liver  enzymes  increased
3--4  days  after  fosfomycin  administration  and  returned  to
normal  levels  within  a  week  to  a  month  after  the  with-
drawal  of  the  drug.  In  our  patient,  the  normalization  of
all  liver  function  tests  took  three  months  to  occur.  In  these
cases,  fosfomycin  induced  hepatotoxicity  was  observed  with
l
p
3
iand  bilirubin  after  fosfomycin  intake.
igher  doses  during  a  longer  period  of  time  than  in  our
atient  (3  g  single  dose),  suggesting  that  its  hepatotoxic
ffect  may  be  dose  independent.  While  the  liver  injury
bserved  in  our  case  can  be  classiﬁed  as  hepatocellular  (ALT
2  upper  limits  of  normal  (ULN)  or  ALT/ALP  ratio  ≥5),  in
he  Chinese  case  it  was  mixed  (ALT  >2  ULN  and  2<  ALT/ALP
atio  >5)  and  in  the  French  case  it  cannot  be  classiﬁed
ecause,  despite  the  elevation  of  ALT,  the  ALP  value  was  not
entioned.
In  our  patient,  acute  hepatitis  appears  to  be  causally
elated  to  the  administration  of  fosfomycin,  based  on  a
emporal  relationship,  negative  serology  for  acute  viral
nfection,  negative  autoantibody  markers,  exclusion  of
ther  drugs  or  other  potentially  hepatotoxic  agents,  and  sug-
estive  histological  alterations  in  the  biopsy.  Liver  biopsy
as  not  performed  in  none  of  the  two  previously  reported
ases,  and  so  these  histological  ﬁndings  cannot  be  com-
ared.  Proof  is  not  possible  in  the  absence  of  a  second
xposition  to  the  drug  for  ethical  reasons.
Based  on  the  ‘‘Roussel  Uclaf  Causality  Assessment  Method
RUCAM)’’  scale,12 a  score  of  9  was  obtained  in  our  patient,
ndicating  that  the  association  between  fosfomycin  and  the
iver  injury  was  ‘‘highly  probable’’.  According  to  the  Maria
nd  Vitorino  scale,13 this  causality  was  considered  to  be
‘possible’’  (score  of  11).
Drug-induced  liver  injury  (DILI)  diagnosis  remains  a  chal-
enge  for  physicians  and  it  is  usually  based  on  exclusion  of
ther  possible  causes  of  hepatic  dysfunction  and  on  the  tem-
oral  association  between  drug  administration  and  the  onset
f  liver  disease.14,15 In  our  case,  hepatic  biopsy  was  a  helpful
ool  to  establish  the  diagnosis.
Although  not  performed  in  our  institution,  the  drug  lym-
hocyte  stimulation  test  (DLST)  is  a  laboratory  test  that  can
e  useful  to  ascertain  the  diagnosis  of  DILI  and  to  identify
 single  causative  drug.  It  consists  in  culturing  a  patient’s
ymphocytes  in  the  presence  of  the  suspected  drug.  Lym-
hocyte  proliferative  response  is  determined  by  monitoring
H-thymidine  uptake.16 It  is  most  frequently  positive  on
mmune  mediated  liver  injury.17 However,  recent  ﬁndings  of
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266  
ssociations  between  speciﬁc  HLA  haplotypes  and  DILI,18--20
hich  does  not  have  hypersensitivity  features,  have  high-
ighted  the  DLST’s  potential  value.21 In  fact,  a  recent
iagnostic  scale,  the  Digestive  Disease  Week-Japan,  already
ncludes  DLST.17 Nevertheless,  low  sensitivity  (around  50%),
ack  of  causality  between  a  positive  result  and  liver  injury,
ack  of  standardization  and  restricted  availability  outside
apan  limit  its  use.21,22 And  so,  some  authors  advocate  that
t  should  be  considered  in  selected  cases,  such  as  those  in
hich  a  single  causative  agent  cannot  be  determined.22 We
onsidered  that  DSLT  was  not  mandatory  in  our  patient  since
osfomycin  was  the  only  drug  used.
In  a  prospective  study,  drug-induced  liver  injury  was
aused  by  a  single  prescription  medication  in  73%  of  the
ases  and  antibiotics  were  the  single  largest  class  of  hep-
totoxic  agents.15
In  summary,  we  report  a  potential  case  of  acute  hepa-
ocellular  lesion  caused  by  fosfomycin.  Being  a  commonly
sed  antibiotic,  physicians  should  be  aware  of  this  rare  but
otentially  serious  adverse  drug  reaction.
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